In a transaction that augments one company's pipeline and gives the other U.S. market access, CancerVax Corp. and Micromet AG signed a definitive merger agreement. (BioWorld Today)

Nuvelo Inc.'s stock benefitted Thursday when the company entered a collaboration with pharmaceutical giant Bayer HealthCare AG to develop and commercialize the cardiovascular drug alfimeprase. (BioWorld Today)

Closing the second tranche of a Series C financing begun two years ago, Novacea Inc. raised more than $25 million - money it will use to launch a Phase III trial with DN-101 to treat advanced prostate cancer. (BioWorld Today)

Signing a deal worth up to $300 million for one product - and possibly more if others come into play - Targacept Inc. partnered worldwide rights to its Phase II cognitive disorder drug, TC-1734, with AstraZeneca plc. (BioWorld Today)